Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Lymphoma Myeloma. 2009 Mar;9(1):74-6. doi: 10.3816/CLM.2009.n.019.

Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.

Author information

  • 1Princess Margaret Hospital, Toronto, Ontario, Canada. christine.chen@uhn.on.ca

Abstract

Bortezomib is a proteasome inhibitor that induces apoptosis in primary Waldenström's macroglobulinemia (WM) cells and WM cell lines. To date, 3 clinical trials of single-agent bortezomib in WM have been published. Of the 64 patients pooled from these studies (most with relapsed/refractory disease), a 25% or greater reduction of IgM was achieved in 78%-85%. Responses were rapid in onset, suggesting a role for bortezomib in the management of hyperviscosity or other settings where rapid IgM reduction is indicated. Neuropathy appears more severe and frequent in WM than in myeloma or other indolent lymphomas treated with bortezomib. Bortezomib-based combination therapies, with consideration for attenuated or intermittent dosing of bortezomib to minimize neuropathy, are under investigation.

PMID:
19362979
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk